Conclusions from an Observational Study of Patients with Vascular Diseases Using the FMSF Technique.
FMSF technique
NADH fluorescence
metabolic regulation
vascular circulation
Journal
Vascular health and risk management
ISSN: 1178-2048
Titre abrégé: Vasc Health Risk Manag
Pays: New Zealand
ID NLM: 101273479
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
10
2023
accepted:
17
11
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
There is great demand for a diagnostic tool for non-invasive assessment of vascular circulation and metabolic regulation. Assessing both these functions is crucial, as each can have a distinct response to hypoxia. The Flow Mediated Skin Fluorescence (FMSF) technique appears uniquely suitable for analysis of vascular circulation and metabolic regulation. In this observational study, the FMSF technique was used to diagnose patients with various vascular diseases. The study group consisted of 482 patients (264 females and 218 males) between the ages of 40-94 years with various vascular problems (arterial hypertension, cardiovascular disease, diabetes, hypercholesterolemia, and chronic venous disease). Three major FMSF parameters were used: Ischemic Response (IR Females were metabolically less adaptive to transient hypoxia than males. However, macrocirculatory function was better in females than among males. Microcirculatory function decreases gradually with age, while macrocirculatory function decreases much more slowly with age, with a tendency to stabilize after 70 years of age.
Identifiants
pubmed: 38025516
doi: 10.2147/VHRM.S442344
pii: 442344
pmc: PMC10676726
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
755-764Informations de copyright
© 2023 Mikosiński et al.
Déclaration de conflit d'intérêts
JK is employed by Angionica Ltd. JG is inventor of patents protecting the use of FMSF technology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Med. 2023 Sep 10;12(18):
pubmed: 37762826
J Appl Physiol (1985). 2008 Jul;105(1):370-2
pubmed: 17932300
Clin Sci (Lond). 2017 May 1;131(9):803-822
pubmed: 28424375
Vasc Health Risk Manag. 2021 Feb 10;17:33-36
pubmed: 33603387
Biology (Basel). 2023 Feb 28;12(3):
pubmed: 36979077
Eur J Histochem. 2014 Dec 12;58(4):2461
pubmed: 25578980
Heart Lung Circ. 2021 Nov;30(11):1637-1646
pubmed: 34452844
Front Physiol. 2020 Jun 19;11:702
pubmed: 32636761
Vasc Health Risk Manag. 2022 Mar 06;18:113-116
pubmed: 35283632
Circ Res. 2022 Feb 18;130(4):566-577
pubmed: 35175845
Biophys J. 2013 Jan 8;104(1):258-67
pubmed: 23332078
Biomark Med. 2010 Apr;4(2):241-63
pubmed: 20406068
Pharmacol Rep. 2015 Aug;67(4):803-10
pubmed: 26321284
Diabetes Care. 2016 Feb;39(2):300-7
pubmed: 26681727
Lancet. 2014 Jun 7;383(9933):1973-80
pubmed: 24613026
Am J Physiol Heart Circ Physiol. 2018 Dec 1;315(6):H1499-H1518
pubmed: 30192631
Eur J Prev Cardiol. 2013 Aug;20(4):531-40
pubmed: 22456692
Front Physiol. 2018 Aug 17;9:1133
pubmed: 30174617
Curr Diab Rep. 2018 Apr 18;18(6):33
pubmed: 29671082